<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03160001</url>
  </required_header>
  <id_info>
    <org_study_id>PRO17050001</org_study_id>
    <nct_id>NCT03160001</nct_id>
  </id_info>
  <brief_title>Niclosamide With Etanercept in Rheumatoid Arthritis</brief_title>
  <official_title>Adjuvant Use of Niclosamide With Etanercept in Rheumatoid Arthritis: Experimental and Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faiq Gorial</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Baghdad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the adjuvant use Niclosamide With Etanercept in Rheumatoid Arthritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized double blind placebo-controlled pilot study (Phase I study) we will assess
      the efficacy and safety of adjuvant use Niclosamide With Etanercept in Rheumatoid Arthritis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Actual">December 10, 2018</completion_date>
  <primary_completion_date type="Actual">August 15, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1 patient group and 1 placebo group</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in disease activity scale</measure>
    <time_frame>Day 1</time_frame>
    <description>Mean change of disease activity index from baseline using clinical disease activity index (CDAI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in disease activity score</measure>
    <time_frame>Day 2</time_frame>
    <description>Mean change of disease activity index from baseline using simplified disease activity index (SDAI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease activity change scale</measure>
    <time_frame>Day 3</time_frame>
    <description>Mean change of disease activity index from baseline using disease activity score 28 joints-erythrocyte sedimentation rate (DAS28-ESR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in disease activity scale</measure>
    <time_frame>24 hours to 48 hours day</time_frame>
    <description>Mean change of disease activity index from baseline using health assessment quality of life (HAQDI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of niclosamide</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of participants with treatment-related adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Placebo and etanercept</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo lactose 500mg cap twice daily with etanercept 50mg weekly for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Niclosamide and etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Niclosamide cap 500 mg twice daily with Etanercept 50mg weekly for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily</description>
    <arm_group_label>Placebo and etanercept</arm_group_label>
    <other_name>Lactose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niclosamide</intervention_name>
    <description>Patients with active RA and receive etanercept with niclosamide cap 500mg twice daily orally as adjuvant therapy for 8 weeks</description>
    <arm_group_label>Niclosamide and etanercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Etanercept 50mg weekly</description>
    <arm_group_label>Niclosamide and etanercept</arm_group_label>
    <arm_group_label>Placebo and etanercept</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with RA, as defined by the American College of Rheumatology (ACR) 1987
             revised criteria or ACR/EULAR 2010,

          -  Severly Active RA by calculating either DAS28 or SDAI or CDAI.

          -  Patient selected are those who started etanercept for less than 3months and still
             active.

        Exclusion Criteria:

          -  Patients on nonsteroidal anti-inflammatory drugs (NSAID) 2 days before entry into this
             study. or methotrexate (MTX)..

          -  Patients with hypersensitivity or severe adverse effects to niclosamide .

          -  Renal impairment.

          -  Hepatic impairment.

          -  Pregnancy or a desire to become pregnant.

          -  Breast feeding.

          -  Patients with Juvenile RA [16 years old or younger].

          -  Patients using other conventional disease modifying antirheumatic drugs (DMARDs).

          -  Patients on steroid.

          -  Patients with coexistence other connective tissue diseases or hypothyroid disease.

          -  Patient with mild or inactive RA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed S Mahmood, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baghdad Teaching Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baghdad teaching Hospital</name>
      <address>
        <city>Baghdad</city>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>December 10, 2018</last_update_submitted>
  <last_update_submitted_qc>December 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Baghdad</investigator_affiliation>
    <investigator_full_name>Faiq Gorial</investigator_full_name>
    <investigator_title>consultant</investigator_title>
  </responsible_party>
  <keyword>Niclosamide</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>diseases activity</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niclosamide</mesh_term>
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

